Clinical Trial

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation. EI-001 has been investigated in human cell cultures, animal studies, and in a Phase 1 healthy volunteer study. The results so far show that EI-001 is a tolerable and potential new treatment for immune diseases such as vitiligo.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-10-29; most recent amendment 2026-06-03.
Status change: Not Yet Recruiting → Recruiting 2025-12-26
Trial Details
NCT Number NCT07223229
Lead Sponsor Elixiron Immunotherapeutics (Hong Kong) Ltd.
Conditions Non-segmental Vitiligo
Enrollment 45 participants
Start Date 2025-12-30
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-05